From hollow-face to nausea and diarrhoea: Experts warn weight loss drug semaglutide isn’t a miracle fix and users can quickly pile pounds on after stopping weekly jabs – as NHS approves Hollywood’s favourite slimming potion
- Semaglutide — sold under the brand name Wegovy — suppresses appetite
- It has been hailed as a miracle by celebs such as Jeremy Clarkson and Elon Musk
- But according to experts, you may pack on the pounds once you stop taking it
A weight-loss jab loved by celebs may not actually be a miracle fix, as experts warn users will likely pile back on the pounds after they stop taking the drug.
Semaglutide, sold under the brand name Wegovy, has been given the green light by watchdog NICE to be used on the NHS.
The drug was described as the ‘most powerful pharmaceutical tool to date’, by one expert.
But Professor Jason Halford, from the School of Psychology at the University of Leeds, also warned users will see rapid weight gain once they have completed their two years of treatment.
The drug, claritin $10 off coupon which costs £73 a month, works by hijacking the brain to suppress appetite and reduce calorie intake, resulting in substantial weight loss.
Elon Musk (left) credits his spectacular weight loss in 2020 to Wegovy. The tech tycoon looked noticeably slim when he first arrived in Twitter HQ after purchasing the company in October (right)
Alex Guevara, 46, (pictured) is a paramedic practitioner from Milton Keynes. He has three children, and lives with his wife Christina, 29. He said: ‘When a friend told me about semaglutide I felt I had nothing to lose. I went to a private clinic, and paid £250 a month for six months’
Trials found those on it lost around 12 per cent of their body weight – and slashed their chances of type 2 diabetes by more than half.
It means patients could be referred for the DIY jabs instead of gastric band or other weight loss surgery, reducing the burden on hospitals and saving the NHS millions.
Professor Halford told Radio 4: ‘I think it’s one of the most powerful pharmaceutical tool to date that we’ve had access to.’
However he said that the drug needs to be taken in the context of specialist weight management services, which he claimed there are not enough of in the UK, making the treatment hard for many to access.
Professor Halford said the drug works by signalling satiety to the brain and suppressing appetite, so once a person stops taking the drug, the weight will likely return.
READ MORE: ‘Game-changing’ weight loss jab Wegovy will be rolled out on NHS in weeks… so will YOU be eligible to get Hollywood’s ‘worst-kept secret’?
‘What we know when you come off the drug at 2 years you see rapid weight gain because you’ve no longer got that drug suppressing appetite systems,’ he said.
But Professor Halford added that once data of the drug’s longer-term effects is available, providing it is deemed safe, it may be used for a much longer period by people who struggle to keep weight off.
Experts welcomed Wegovy’s recommendation for those with a Body Mass Index (BMI) of 30 and above, as part of a weight-loss programme of diet and exercise.
Tam Fry, from the National Obesity Forum, said this is ‘the weight-loss drug that we’ve been waiting for’ and urged health leaders to ration supplies to those in greatest need.
He said: ‘It’s a gamechanger and so successful that Hollywood A-listers are now using it to slim and show off their figures.
‘The real danger is that there may not be enough to go round in the short-term.
‘You should not be using it just to lose a few pounds because that might will jeopardise the health of those who really need it, those who have diabetes Type 2 and morbid obesity.’
The drug has been hailed a miracle cure by some who have taken it.
Semaglutide, marketed as Wegovy to those who are overweight or obese, will be available in pharmacies from the spring
Kim Kardashian is rumoured to have used Wegovy to rapidly lose weight in order to fit in Marilyn Monroe’s famous ‘Happy Birthday Mr President’ dress at the 2022 Met Gala (pictured)
Ms Rice (pictured) lost 50pounds on Wegovy after using it for the last six months
Alex Guevara, 46, is a paramedic practitioner from Milton Keynes. He has two children from his first marriage, and a third with wife Christina, 29, who’s also a paramedic.
He said by April lastyear he was touching 20st and his weight left him feeling suicidal.
Mr Guevara started on semaglutide and within a few days said he started feeling less hungry and felt much happier.
‘I needed something dramatic to break the cycle and stop me hurtling towards type 2 diabetes, cardiovascular diseases and stroke,’ he added. ‘Semaglutide should be available to anyone who needs it.’
Made by Novo Nordisk, it is hoped the jabs – which will initially help around 35,000 people a year – will be available to patients within weeks as part of NHS specialist weight management services.
Wegovy and Ozempic work by triggering the body to produce a hormone called glucagon-like peptide-1 that is released naturally from the intestines after meals
A UK study found that people who used Wegovy experienced rapid weight loss, dropping 18% of their weight over 68 weeks. They regained two-thirds of that weight, or 12% of their original body weight in the year after dropping the weekly injections. Experts says the drug needs to be used over a lifetime to keep off the pounds
Top Gear host Jeremy Clarkson (left) revealed he was taking Ozempic in a bid to lose weight. When asked in October whether following a healthier diet or hitting the gym was behind his 30lb (13.6kg) weight loss, Elon Musk (right) credited ‘fasting’ and ‘Wegovy’
The drugs work by suppressing appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating, making people feel so they eat less and lose weight.
Adults with a BMI classed as obese and at least one weight-related illness such as pre-diabetes, type 2 diabetes, high blood pressure, cardiovascular disease or high blood pressure, could qualify.
The jabs are self-administered by patients once a week using pre-filled pens, for a minimum of 16 weeks.
Patients can initially be placed on the drug for a maximum of two years, although regulators say there is scope to increase this if real-world data shows it continues to be an effective weight loss tool.
Around 19million people in England are obese, which costs the NHS more than £6billion a year.
Will YOU be eligible for the once-a-week jab?
WHO IS ELIGIBLE?
Wegovy will be available for people who have a BMI of 35 — making them morbidly obese.
Patients must also have at least one weight-related comorbidity, such as type 2 diabetes, to be eligible.
Adults with a BMI between 30 and 35 could also be recommended the drug if they have been referred for specialist help.
HOW TO WORK OUT YOUR BMI
BMI = (weight in kilograms / (height in meters x height in meters))
Under 18.5: Underweight
18.5 – 24.9: Healthy
25 – 29.9: Overweight
30 – 34.9: Obese
35 or greater: Morbidly obese
Trials found patients given the weekly jab lost a tenth of their body weight in just 20 weeks – 25 times more than those on a placebo – consuming around 35 per cent fewer calories.
Overweight and obese participants given regular doses also saw their odds of suffering type 2 diabetes fall by up to 61 per cent.
Obesity expert Alex Miras, a professor of endocrinology at Ulster University, said it will make a massive difference to people living with obesity.
‘This decision made by NICE is a pivotal moment for the treatment of people living with obesity,’ he said, adding: ‘The weight loss that can be achieved with this safe medication is substantial and likely to lead to the improvement of obesity related complications in a large number of patients.’
The drug is already prescribed at much lower doses to treat patients with type 2 diabetes, under the brand name Ozempic.
It has led celebrities Elon Musk and Jeremy Clarkson to both publicly credit it with helping them to shift the pounds.
Meanwhile, Kim Kardashian was rumoured to have used it to rapidly lose 16lbs (7.3kg) to fit into Marilyn Monroe’s iconic ‘Happy Birthday Mr President’ dress at the 2022 Met Gala.
However, it is not without side effects with users commonly complaining of nausea, constipation and diarrhoea after taking the medication.
It has also been known to make food less appealing, potentially ruining the enjoyment of eating altogether.
Helen Knight, director of medicines evaluation at NICE, said: ‘For some people losing weight is a real challenge which is why a medicine like semaglutide is a welcome option.’
Dietitian Dr Duane Mellor, of Aston Medical School, Aston University, said: ‘It is important to remember that semaglutide works alongside and supports healthy lifestyle changes and when people are being offered semaglutide that they are also given ongoing support to make changes and maintain these changes with respect to diet and lifestyle.
‘As all individuals initially being offered semaglutide via the NHS will be supported by specialist weight management services this should including support from a specialist dietitian.’
WHAT SHOULD A BALANCED DIET LOOK LIKE?
Meals should be based on potatoes, bread, rice, pasta or other starchy carbohydrates, ideally wholegrain, according to the NHS
• Eat at least 5 portions of a variety of fruit and vegetables every day. All fresh, frozen, dried and canned fruit and vegetables count
• Base meals on potatoes, bread, rice, pasta or other starchy carbohydrates, ideally wholegrain
• 30 grams of fibre a day: This is the same as eating all of the following: 5 portions of fruit and vegetables, 2 whole-wheat cereal biscuits, 2 thick slices of wholemeal bread and large baked potato with the skin on
• Have some dairy or dairy alternatives (such as soya drinks) choosing lower fat and lower sugar options
• Eat some beans, pulses, fish, eggs, meat and other proteins (including 2 portions of fish every week, one of which should be oily)
• Choose unsaturated oils and spreads and consuming in small amounts
• Drink 6-8 cups/glasses of water a day
• Adults should have less than 6g of salt and 20g of saturated fat for women or 30g for men a day
Source: NHS Eatwell Guide
Source: Read Full Article